

Special Issue

Adeno-Associated Virus (AAV) for Gene Therapy

Message from the Guest Editor

Adeno-associated virus (AAV) based vector have arguably emerged as the leading gene therapy modality. Below is a (non-inclusive) list of areas that are of special interest for the current special guest issue of *Viruses*.

- Approaches to reduce the vector dose without negatively influencing transduction efficiencies (e.g., the development of viruses with a more favorable transduction profile, more efficient routes of administration, understanding the basic biology of AAVs – particular in vivo models etc.);
- Developing methods to determine the *human* tropism of AAV serotypes/variants;
- Identifying the best model(s) to study AAV tropism, based on knowledge gained by the ability to determine the *human* tropism;
- Reduction of an innate immune response upon vector administration;
- Reduction of an adaptive immune response due to treatment with AAV vectors;
- Approaches to mitigate the deleterious effect of pre-existing immunity against the AAV serotype/variant used;
- The development of methods that allow vector re-administration;
- AAV vector manufacturing platforms;
- AAV vector quality control.

Guest Editor

Dr. Thomas Weber

Spark Therapeutics Inc., Philadelphia, PA, USA

Deadline for manuscript submissions

closed (30 September 2024)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/177437

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).